Vimarsana
Biggest News Aggregation in the World

Page 8 - Repeatable Battery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Repeatable Battery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Repeatable Battery Today - Breaking & Trending Today

University of Arkansas Publishes a New Study on the Cognitive Benefits of Nutrition21's Sports Performance Ingredient, Nitrosigine® - Vimarsana News

University of Arkansas Publishes a New Study on the Cognitive Benefits of Nutrition21's Sports Performance Ingredient, Nitrosigine®

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Impairments in Some Cognitive Domains in Patients With Sickle Cell Disease - Vimarsana News

Impairments in Some Cognitive Domains in Patients With Sickle Cell Disease

Patients with sickle cell disease showed impairments in some cognitive domains compared with healthy control individuals, according to a new study.

Cognitive function of older adults could be improved through multidomain lifestyle interventions - Vimarsana News

Cognitive function of older adults could be improved through multidomain lifestyle interventions

Aging-US published "Facility-based and home-based multidomain interventions including cognitive training, exercise, diet, vascular risk management, and motivation for older adults: a randomized controlled feasibility trial" which reported that in an outcome assessor-blinded, randomized controlled trial, participants without dementia and with one or more modifiable dementia risk factors, aged 60-79 years, were randomly assigned to the facility-based MI, the home-based MI, or the control group receiving general health advice.

New Data from Past BACE Inhibitor Trials Shed Light on Side Effects - Vimarsana News

New Data from Past BACE Inhibitor Trials Shed Light on Side Effects

16 Dec 2020 BACE inhibitors succeeded in stemming the tide of Aβ production in the brain, but the drugs also slightly dulled cognition and shrank the brain, bringing the trials to a screeching halt. Rather than washing their hands of a failure and moving on, researchers continue to dig through the trial data to find out exactly what happened, and perhaps even to chart a way forward for the drugs. Three recent studies—all led by Michael Egan at Merck—add new insight. Verubecestat triggered a rapid atrophy that did not get worse. This happened in amyloid-rich regions, and did not track wit...